IgG4-Related Disease: Navigating Diagnosis and the Expanding B-Cell-Targeted Treatment Landscape - Episode 5
The Cost of Delayed IgG4-RD Diagnosis: Organ Damage and Relapse
Most organ damage in IgG4-related disease occurs before diagnosis, and roughly 90% of patients relapse within 3 years. The panel explains why early recognition and continuous surveillance are essential.
In "The Cost of Delayed IgG4-RD Diagnosis: Organ Damage and Relapse," the panel explores why timely recognition matters so much in a disease that can progress silently.
Dr. Culver asks Dr. Katz what he tells patients and physicians about early diagnosis and the risk of damage. He calls this one of the greatest areas of need in the IgG4-related disease community. The disease can be asymptomatic and indolent. Patients may have active disease for a long time before they seek medical attention. Even after they do, significant diagnostic delays are common because the disease is still poorly recognized.
Dr. Katz notes that the disease has a high propensity for fibrosis and can fly under the radar for years. As a result, patients can carry a heavy burden of damage in any involved organ. Some damage reflects longstanding inflammation leading to organ dysfunction. The pancreas is by far the most common example. Patients may develop endocrine insufficiency, often insulin-dependent diabetes, and exocrine insufficiency requiring pancreatic enzyme supplementation.
In his center's experience, most damage occurs before clinicians even meet the patient. Many patients caught early start treatment before damage develops. Once treatment begins, he sees very little new damage.
On relapse, Dr. Katz describes the risk as overwhelmingly high. Around 90% of patients relapse within 3 years of initial presentation. Some single-organ manifestations relapse less often. Patients without risk factors may sometimes avoid relapse. Those risk factors include elevated serum IgG4 and IgE, hypocomplementemia, and eosinophilia. He tells patients on the first day that current treatments can reliably control the disease in nearly everyone. However, no one knows how long control will last.
Dr. Katz therefore insists on ongoing surveillance even when patients feel well. Monitoring includes symptoms, physical examination, frequent laboratory tests, and repeated imaging throughout follow-up. Dr. Culver closes by underscoring how inadequate treatment raises the risk of damage. She also stresses patient education about why treatment matters.
Our next episode, "B Cells in IgG4-RD Pathogenesis and Setting Treatment Goals," features Dr. Della Torre on what is known about disease biology and Dr. Katz on what treatment should achieve.
